Therapeutic augmentation of ketogenic diet with a sodium-glucose cotransporter 2 inhibitor in a super-refractory status epilepticus patient

SGLT2 inhibitors may have a therapeutic value in SRSE patients who cannot achieve ketosis with KD alone.